MedPath

Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Completed
Conditions
Hypertrophic Cardiomyopathy
Interventions
Device: Cardioverter-defibrillator
Registration Number
NCT04402268
Lead Sponsor
Poznan University of Medical Sciences
Brief Summary

Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes. The structural and functional abnormalities cannot be explained by flow-limiting coronary artery disease or loading conditions. The disease affects at least 0,2% of the population worldwide and is the most common cause of sudden cardiac death (SCD) in young people and competitive athletes due to fatal ventricular arrhythmia, but in most patients, however, HCM has a benign course. Therefore, it is of utmost importance to properly evaluate patients and identify those who would benefit from a cardioverter-defibrillator (ICD) implantation.

Detailed Description

Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes. The structural and functional abnormalities cannot be explained by flow-limiting coronary artery disease or loading conditions. The disease affects at least 0,2% of the population worldwide and is the most common cause of sudden cardiac death (SCD) in young people and competitive athletes due to fatal ventricular arrhythmia, but in most patients, however, HCM has a benign course. Therefore, it is of utmost importance to properly evaluate patients and identify those who would benefit from a cardioverter-defibrillator (ICD) implantation.

This study assesses the accuracy of the HCM SCD-Risk Calculator, recommended by European Society of Cardiology guidelines, in patients treated in the Ist Department of Cardiology of Poznan University of Medical Sciences from 2005 to 2018.

The study group consisted of 252 patients aged 20-88 (mean 53,8 ± 15,1, median 54); 49,6% were men. The protocol consisted of medical history collection (including a questionnaire), physical examination and additional tests such as echocardiography with the assessment of global longitudinal strain and average strain, cardiac magnetic resonance, ambulatory ECG monitoring, control of implantable devices and exercise testing.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
252
Inclusion Criteria
  1. Hypertrophic cardiomyopathy,
  2. Minimum 18 years,
  3. Questionnaire,
  4. Assessment of HCM SCD-Risk Calculator at the beginning of the observation,
  5. Regular visits in Cardiology Outpatient Clinic,
  6. Agreement to participate in the study
Exclusion Criteria
  1. Poorly controlled hypertension (systolic pressure on the next two visits in the Cardiology Outpatient Clinic >180 mmHg),
  2. Haemodynamically significant valvular heart disease or valve replacement condition,
  3. Past myocardial infarction (haemodynamically significant changes found in coronarography),
  4. Heart transplant,
  5. Insufficient amount of data from the subject and additional tests allowing for further analysis,
  6. Lack of consent to participate in the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Low riskCardioverter-defibrillatorLow risk of sudden cardiac death according to HCM Risk-SCD Calculator
High riskCardioverter-defibrillatorHigh risk of sudden cardiac death according to HCM Risk-SCD Calculator
Intermediate riskCardioverter-defibrillatorIntermediate risk of sudden cardiac death according to HCM Risk-SCD Calculator
Primary Outcome Measures
NameTimeMethod
Sudden cardiac death (SCD) in risk groups2005-2018

Number of SCD cases in each of risk groups according to HCM Risk-SCD Calculator

Secondary Outcome Measures
NameTimeMethod
New risk factors of sudden cardiac death (SCD)2005-2018

New echocardiographic features, such as glibal longitudinal strain, average strain, left atrial volume index, which allow to better estimate the risk of SCD

Trial Locations

Locations (1)

Poznan Univeristy of Medical Sciences

🇵🇱

Poznań, Wielkopolska, Poland

© Copyright 2025. All Rights Reserved by MedPath